NRG1 cancers

Merusā€™ Zeno Improves Outcomes in NRG1+ Cancers (ESMO 2023)
ESMO 2023

Merusā€™ Zeno Shows Higher Response Rates in NRG1+ Pancreatic and Lung Cancers (ESMO 2023)

Anika Sharma

ESMO 2023: 1618P Currently, Ipsen’s Onivyde is the standard of care, but it offers only a 7% chance of response ...

Pharmtales - your go-to source for comprehensive coverage of the pharmaceutical industry.

pharmtales
Latest Pharma News & Insights

Ā© 2024 pharmtales.com | All rights reserved.

PRIVACY POLICY terms of service Contact us